Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid Tumors
Public ClinicalTrials.gov record NCT07517198. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1, Multicenter, Open-Label, Dose-Escalation Study to Assess Safety, Tolerability, and Efficacy of EXS74539 as Monotherapy in Participants With Select Solid Tumors
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The primary purpose of this study is to determine the safety, tolerability, and maximum tolerated dose (MTD) of EXS74539 (REC-4539) in participants with select solid tumors.
Study identification
- NCT ID
- NCT07517198
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 1
- Lead sponsor
- Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.
- Industry
- Enrollment
- 40 participants
Conditions and interventions
Conditions
- Solid Tumor
- Small Cell Lung Cancer (SCLC)
- High Grade Neuroendocrine Cancer
- Small Cell Carcinomas of Non-lung Origin
- Non-small Cell Lung Cancer (NSCLC)
- Prostate Cancer
- Ovarian Cancer
- Renal Carcinoma (Clear and Non-clear Cell)
- Head and Neck Squamous Cell Carcinoma (HNSCC)
- Hepatic Cancer
- Gastric Cancer
- Triple-negative Breast Cancer (TNBC)
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 12, 2026
- Primary completion
- Feb 28, 2029
- Completion
- Feb 28, 2029
- Last update posted
- Jun 9, 2026
2026 – 2029
United States locations
- U.S. sites
- 3
- U.S. states
- 3
- U.S. cities
- 3
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Start Lacn | Los Angeles | California | 90025 | Recruiting |
| START Dallas | Fort Worth | Texas | 76104 | Recruiting |
| START Mountain Region | West Valley City | Utah | 84119 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT07517198, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 9, 2026 · Synced Sep 5, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT07517198 live on ClinicalTrials.gov.